Celonic will manufacture over 100 million doses of Curevac's COVID-19 Vaccine Candidate, CVnCoV CureVac and Celonic Group have conclud a partnership for the production of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV. CureVac began development of mRNA-based COVID-19 vaccine candidates in January 2020 and CVnCoV is the vaccine candidate chosen for…..
First human model for Leigh syndrome [caption id="attachment_9893" align="alignright" width="300"] Human brain organoids with mature neurons in green. ©Dr. Agnieszka Rybak-Wolf[/caption] Leigh syndrome is the most severe mitochondrial disease in children. This orphan disease causes severe muscle weakness, movement defects, and intellectual disabilities. It usually leads to death within the…..
Charcot-Marie Tooth disease: A 100% French RNA-based therapeutic innovation Charcot-Marie Tooth disease is the most common hereditary neurological disease in the world. It affects the peripheral nerves and causes progressive paralysis of the legs and hands. No treatment is currently available to fight this disease, which is due to the…..
ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases
ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases ConserV Bioscience, a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases, and eTheRNA, a clinical-stage immunotherapy company focused on mRNA antigen delivery and immunostimulation using its TriMix technology,…..
Biogen plans to build a new gene therapy manufacturing facility in Research Triangle Park Biogen, a pioneer in neurosciences, plans to build a new gene therapy manufacturing facility at its Research Triangle Park (RTP) manufacturing campuses in North Carolina to support its growing gene therapy pipeline across multiple therapeutic areas.…..
VIVEbiotech expands facilities to increase innovation and manufacturing capabilities of specialist lentiviral vectors
VIVEbiotech expands facilities to increase innovation and manufacturing capabilities of specialist lentiviral vectors VIVEbiotech, a Spanish CDMO focused on the manufacture of lentiviral vectors from R&D early stages to GMP, is expanding its manufacturing capabilities with new facilities. This expansion will enable increased production capacity and the further optimization of…..